Whether or not breast cancer screening results in a reduction in mortality from the disease, it is clear from several studies that screening yields tumours that are smaller, more likely to be in situ and clinically less advanced (Linell et al., 1980; Gibbs, 1985; Anderson et al., 1986; Roberts et al., 1990 al., 1982], Amersham) diluted 1/40 in 1/5 normal swine serum. The sections were then incubated for 30min with biotinylated sheep-anti-mouse serum (Amersham) and streptavidinbiotin peroxidase complex for 30min, being washed with TBS between stages. The chromagen and counterstain were as for the c-erbB-2 method above. A section of human placenta was used as a control.
Whether or not breast cancer screening results in a reduction in mortality from the disease, it is clear from several studies that screening yields tumours that are smaller, more likely to be in situ and clinically less advanced (Linell et al., 1980; Gibbs, 1985; Anderson et al., 1986; Roberts et al., 1990) . The question arises as to whether screen detected cancers differ biologically from those presenting clinically; the aim of this study was to determine whether the two groups differed in their expression of antigens that are associated with differing biological behaviour in terms of prognosis. Three antigens, currently of interest as prognostic indicators were chosen. Amplification of c-erbB-2 is regarded as a reliable prognostic marker in breast cancer (Barnes, 1989) , epidermial growth factor receptor (EGFR) correlates strongly with a short disease free interval (Lewis et al., 1990 ) and positive immunostaining for the oestrogen regulated protein cathepsin D is associated with prognostic advantage ).
Materials and methods
Tumour tissue from 180 carcinomas was studied. Of these, 69 tumours derived from clinical presentation whereas 111 tumours were detected by breast cancer screening. The latter group comprised 80 tumours detected by population screening (UK National Health Service Breast-Screening Programme) and 31 tumours via a charity-sponsored breast screening service. The symptomatic tumours were from consecutive patients investigated and treated at the same hospital over the same period of time as those of the screened group.
Specimens were obtained immediately after removal, measured and described, and when possible a portion of tumour snap frozen and stored at -70°C. Representative blocks were fixed immediately in 10% buffered formol saline and one block post fixed in mercuric chloride.
All invasive tumours (ductal and lobular) were graded by Elston's modification of the Bloom and Richardson method (Elston, 1987) . The immunohistochemical preparations were independently scored by two observers without knowledge of the derivation of the tumours; discrepancies were resolved by conference with a two headed microscope.
Immunohistochemistry c-erbB-2 oncoprotein Paraffin sections of tissue postfixed in mercuric chloride were cut at 4 1f, dewaxed and rehydrated.
After treatment with 0.5% hydrogen peroxide in methanol for 10 min the sections were washed and placed in TRISbuffered saline (TBS) for 5 min. They were then covered with 1/5 normal swine serum for 10 min after which excess serum was removed and replaced by mouse monoclonal antibody (NCL-CBl [Corbett et al., 1990] [Waterfield et al., 1982] , Amersham) diluted 1/40 in 1/5 normal swine serum. The sections were then incubated for 30min with biotinylated sheep-anti-mouse serum (Amersham) and streptavidinbiotin peroxidase complex for 30min, being washed with TBS between stages. The chromagen and counterstain were as for the c-erbB-2 method above. A section of human placenta was used as a control.
Tumours were scored on a basis of intensity and distribution of staining as previously described (Horne, 1987 [Reid et al., 1986] ) diluted 1:400 for 30 min at RT. After two changes of TBS they were incubated with biotinylated donkey-anti-rabbit serum (Amersham) and streptavidin-biotin peroxidase complex for 30 min, being washed with TBS between stages. The chromagen and counterstain were as for the c-erbB-2 method above.
Tumours were scored for intensity of staining as previously described ) and placed in three grades, 0, no cell staining; 1, moderate staining; 2, strong staining.
Staining of macrophages was ignored. For this study tumour staining of grade 1 or 2 was regarded as positive for purposes of analysis.
Results
Size, grade, invasion status, lymph node status Our results demonstrate certain differences between screen detected cancers and those presenting clinically. Tumours within the screened group were more often of small size; 37% of screened tumours measured less than 15 mm compared with 15% of clinical tumours (P<0.005, Figure 2c ). Further, whereas tumour grades were fairly evenly distributed in the clinical group, the screened group contained relatively few grade III lesions (P <0.025, Figure 2d ). Differences were also evident in the invasion status, in situ disease being uncommon (3%) in the clinical cases yet comprising 16% of screened tumours (P<0.05, Figure 2b ). This difference is reflected in the lymph node status where 35% of the clinical cases had axillary metastases compared with 14% of screened patients (Figure 2a ).
Immunohistochemistry
Immunostaining for EGFR using monoclonal antibody EGFR1 showed generally a cytoplasmic pattern, although in some cases membrane associated labelling was observed (Figure la) . Immunostaining for c-erbB-2 using monoclonal antibody NCL-CB 11 gave, in all positive cases, intense membrane associated staining (Figure lb) . Using the polyclonal antiserum, for cathepsin D a granular cytoplasmic staining pattern was observed (Figure lc) .
Comparing screened and unscreened tumours, there was a significant difference in the expression of cathepsin D between the two groups. Almost equal positive and negative scores were recorded in the clinical group, whereas there was a marked tendency towards cathepsin D positivity in the screened group (P<0.05, Figure 3a) . Eliminating non-invasive carcinomas from the analysis and considering invasive carcinomas only, an excess of cathepsin D positive tumours was observed in the screened group, although falling just short of significance (Figure 3b) . A similar proportion of patients in the screened and unscreened groups expressed EGFR and c-erbB-2 (Figure 4a and b) .
Invasion status did not relate to cathepsin D expression or EGFR expression. Whilst a higher proportion of in situ tumours were c-erbB-2 positive (5/19:' 26%) compared to invasive lesions (20/139: 14%), this did not achieve significance. There was a significant tendency towards co-expression of c-erbB-2 and EGFR (P<0.01, Figure 5a ). There was a significant association between high histological grade and positive c-erbB-2 status ( Figure Sb) .
Discussion
The patients within our screen detected group were largely from a prevalence screen, i.e. the first screen a patient has, detecting all prevalent disease. As expected, this yielded a number of large tumours, often palpable, measuring up to 60 mm and other examples of advanced disease. All but four the tumours were clinically stage I or II. None had evident distant metastases but skin was locally involved in two patients from each group. Despite this bias, diluting the screened group with tumours that would not be expected within second and subsequent (incidence) screens, our results demonstrate certain differences between the screen detected cancers and those presenting clinically. The differences relating to smaller size, lower grade, higher incidence of in situ disease and lower incidence of lymph node metastases within the screened group are in accordance with previous work (Gibbs, 1985; Anderson et al., 1986) .
Overexpression of c-erbB-2 oncoprotein is regarded by Screened cancers tend to be lymph node negative, non-invasive, small and of low histological grade, compared to the nonscreened group. most workers to equate with poor prognosis (Barnes, 1989; Slamon et al., 1987; Wright et al., 1989; Varley et al., 1987; Zhou et al., 1987) although this is not a universal finding, perhaps due to differences in methodology between authors (Press, 1990 'clinical' group of tumours; our finding of equal incidence of expression in the two groups is perhaps due to the higher proportion of DCIS within the screened group. The number of cases falling into the c-erbB-2 positive category is, however, small in the series of tumours collected so far, and it may be that differences between screened and unscreened cases will emerge with greater numbers.
Again, the presence of epidermal growth factor receptor in human breast cancer is associated with poor prognosis (Sainsbury et al., 1985; Sainsbury et al., 1987) although not with tumour size or lymph node status (Sainsbury et al., 1987; Sainsbury et al., 1988; Toi et al., 1990) ; some workers find an association with histological grade (Toi et al., 1990) whereas others do not (Lewis et al., 1990) . The proportion of cases overall scored positive for EGFR was 30% (40/132) and was similar to that assessed as 'positive' by Sainsbury et al. (1987) using radioligand binding assays, but somewhat higher than the proportion scored positive by Lewis et al. (1990) (14%) who also used an immunohistochemical method. The differences in tumour size, lymph node status and grade that we find between the screened and 'clinical' groups are not reflected in the EGFR status that is essentially similar in the two groups, but our results do demonstrate an association between expression of EGFR and c-erbB-2 protein. There have been no previous reports of co-expression of c-erbB-2 and EGFR and this may be a chance finding. Patients shown to express both proteins have a particularly poor prognosis (Wright, 1989) .
Cathepsin D is an aspartic proteinase, a proteolytic enzyme widely distributed in human tissues and often expressed in mononuclear phagocytes (Reid et al., 1986) . It is synthesised in the form of a precursor and in the human breast is secreted in greater amount by cancer cells than by normal mammary cells (Capony et al., 1989 (Maudelonde et al., 1988; Thorpe et al., 1989; Spyratos et al., 1989; Tandon et al., 1990 ) yet Henry et al. (1990 (Figure 3a and 3b) (Clark et al., 1984; Stebbings et al., 1989; Tinnemans et al., 1990) . Our results, although based on a relatively small series, therefore lend further credence to the view that screen detected breast cancers do indeed represent tumours at an earlier stage in their development. An alternative interpretation of this finding is suggested by the fact that the apparent incidence of invasive breast cancer in screened populations is at least 40% higher than in an equivalent non-screened group (UK Trial, 1988) . This indicates that many of the cancers detected by screening would not have presented clinically, for whatever reason (slow growth, regression). Thus the increased expression of cathepsin D may reflect the possibility that screening picks up, in part, cancers that are biologically distinct from those presenting clinically. The fact that cathepsin D is a marker of less aggressive tumour behaviour supports the view that screened cancers tend to be better differentiated and might never have presented clinically, or have pursued a relatively benign course without metastasis. This hypothesis would explain in part failure of some screening programmes to yield a significant reduction in mortality (UK Trial, 1988 
